公开(公告)号：US20220259288A1

公开(公告)日：2022-08-18

申请号：US17486820

申请日：2021-09-27

申请人： LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

发明人： Klaus LEY ,  Alessandro SETTE

IPC分类号： C07K14/775 ,  A61P9/10 ,  A61K38/17 ,  A61K39/00 ,  C07K7/08 ,  A61K38/10 ,  A61P1/16

摘要： Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders.

公开(公告)号：US10385340B2

公开(公告)日：2019-08-20

申请号：US14937439

申请日：2015-11-10

申请人： La Jolla Institute For Allergy and Immunology

发明人： Nunzio Bottini ,  Stephanie Stanford

IPC分类号： C12N15/113 ,  A61K38/00 ,  C07K16/40

摘要： There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.

公开(公告)号：US10370438B2

公开(公告)日：2019-08-06

申请号：US14462424

申请日：2014-08-18

申请人： LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

发明人： Toshiaki Kawakami ,  Yuko Kawakami

IPC分类号： C07K7/08 ,  C07K14/47 ,  C07K14/52 ,  C07K16/18 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395

摘要： Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to reduce or decrease the probability, severity, frequency, duration or prevent a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation.

公开(公告)号：US10308689B2

公开(公告)日：2019-06-04

申请号：US14800468

申请日：2015-07-15

申请人： LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

发明人： Sujan Shresta ,  Lauren Yauch ,  Alessandro Sette ,  Daniela Weiskopf

IPC分类号： C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  G01N33/569 ,  A61K39/00

摘要： Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8+ T cell response or an anti-DV CD4+ T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.

公开(公告)号：US20180335433A1

公开(公告)日：2018-11-22

申请号：US15914670

申请日：2018-03-07

申请人： La Jolla Institute for Allergy and Immunology

发明人： Amnon Altman ,  Kok-Fai Kong

IPC分类号： G01N33/573 ,  C12N9/12 ,  A61K38/00

CPC分类号： G01N33/573 ,  A61K38/00 ,  C07K2319/10 ,  C12N9/1205 ,  C12Y207/11013 ,  G01N2500/02

摘要： The invention relates to compositions, methods and uses of inhibitors of binding between PKCθ and CD28, and modulating an undesirable or aberrant immune response, disorder or disease, an inflammatory response, disorder or disease, inflammation or an autoimmune response, disorder or disease. Compositions include inhibitors of binding between PKCθ and CD28, which include, among others, PKCθ, CD28 and Lck sequences, subsequences, variants and modified forms, and polymorphisms.

公开(公告)号：US20140044703A1

公开(公告)日：2014-02-13

申请号：US13601823

申请日：2012-08-31

申请人： SHINICHIRO KATO ,  Rachel Soloff Nugent ,  Hitoshi Yoshida ,  Michael Croft

发明人： SHINICHIRO KATO ,  Rachel Soloff Nugent ,  Hitoshi Yoshida ,  Michael Croft

IPC分类号： C07K16/28

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2799/026

摘要： The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

摘要翻译： 本发明提供特异性结合OX40（CD134），称为OX40抗体，抗OX40或抗OX40抗体的抗体。 特异性结合OX40的本发明抗体包括哺乳动物（人，灵长类动物等），人源化和嵌合抗OX40抗体。 特异性结合OX40的本发明抗体和抗体子序列（片段）包括纯化和分离的抗体及其药物制剂，可用于各种方法，包括治疗，筛选和检测方法。

公开(公告)号：US20130108602A1

公开(公告)日：2013-05-02

申请号：US13646183

申请日：2012-10-05

申请人： LA JOLLA INSTITUTE FOR ALLERGY AND IMMU

发明人： Catherine C. Hedrick ,  Klaus Ley ,  Richard Hanna ,  Iftach Shaked

IPC分类号： A61K38/17 ,  A61K31/404 ,  A61K31/235 ,  A61K35/14

CPC分类号： A61K38/1783 ,  A61K31/216 ,  A61K31/235 ,  A61K31/404 ,  A61K35/15 ,  A61K38/00 ,  C07K14/70567

摘要： Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject; decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject; and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse cardiovascular event or cardiovascular disease in a subject, are provided. Methods include, for example, administering a Nur77 polypeptide or subsequence thereof, a Nur77 agonist, or CD14+ CD16+ monocytes or CD14dimCD16+ (CD115+CD11b+GR1− (Ly6C−)) monocytes or macrophages to a subject to decrease, reduce, inhibit, suppress, limit or control the underlying condition or an adverse symptom or pathology of the condition.

摘要翻译： 降低，减少，抑制，抑制，限制或控制受试者中不良或异常免疫应答，免疫疾病，炎症反应或炎症的方法; 减少，减少，抑制，抑制，限制或控制受试者的自身免疫应答，病症或疾病; 并且提供减少，减少，抑制，抑制，限制或控制受试者中不利的心血管事件或心血管疾病。 方法包括例如将Nur77多肽或其子序列，Nur77激动剂或CD14 + CD16 +单核细胞或CD14dimCD16 +（CD115 + CD11b + GR1-（Ly6C-））单核细胞或巨噬细胞给予受试者以减少，减少，抑制，抑制 ，限制或控制病症的基础状况或不良症状或病态。

公开(公告)号：US20120251505A1

公开(公告)日：2012-10-04

申请号：US13394010

申请日：2010-09-03

申请人： Carl F. Ware ,  Vasileios Bekiaris

发明人： Carl F. Ware ,  Vasileios Bekiaris

IPC分类号： A61K35/26 ,  C12Q1/04 ,  G01N33/569 ,  A61P31/18 ,  C12Q1/02 ,  C40B30/06 ,  A61P31/22 ,  C12N5/0789 ,  C12Q1/68

CPC分类号： G01N33/5047 ,  A61K35/00 ,  C12N5/0651 ,  C12N2501/2307 ,  C12N2502/256

摘要： The invention provides human lymphoid tissue inducer (LTi) cells, methods of producing human lymphoid tissue inducer (LTi) cells, and methods of using human lymphoid tissue inducer (LTi) cells. Such methods include treatment of a subject that would benefit from human lymphoid tissue inducer (LTi) cells, for example, an immunocompromised or immunosuppressed subject.

摘要翻译： 本发明提供人类淋巴组织诱导物（LTi）细胞，产生人淋巴组织诱导物（LTi）细胞的方法，以及使用人类淋巴组织诱导物（LTi）细胞的方法。 这样的方法包括治疗受益于人类淋巴组织诱导物（LTi）细胞的受试者，例如免疫受损或免疫抑制受试者。

公开(公告)号：US20120141465A1

公开(公告)日：2012-06-07

申请号：US11867621

申请日：2007-10-04

申请人： MICHAEL CROFT ,  Shahram Salek-Ardakani ,  Magdalini Moutaftsi ,  Alessandro Sette ,  Carl F. Ware

发明人： MICHAEL CROFT ,  Shahram Salek-Ardakani ,  Magdalini Moutaftsi ,  Alessandro Sette ,  Carl F. Ware

IPC分类号： A61K39/42 ,  A61K35/76 ,  A61K39/29 ,  A61K39/275 ,  A61K39/12 ,  A61K39/21

CPC分类号： C07K16/2878 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/5254 ,  A61K2039/55516 ,  C07K2317/75 ,  C12N2710/24134

摘要： The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.

摘要翻译： 本发明涉及使用OX40（CD134），TNFR超家族蛋白质激动剂的组合物和方法。 本发明包括单独施用OX40激动剂或与病毒抗原或活或减毒病毒组合以治疗病毒感染或用于疫苗接种或免疫接种的本发明。

公开(公告)号：US08153123B2

公开(公告)日：2012-04-10

申请号：US12483159

申请日：2009-06-11

申请人： Carl F. Ware ,  Carl De Trez

发明人： Carl F. Ware ,  Carl De Trez

IPC分类号： A61K39/395

CPC分类号： G01N33/5088 ,  A61K2039/505 ,  C07K16/242 ,  G01N33/5047 ,  G01N2333/70517 ,  G01N2333/70575 ,  G01N2800/24

摘要： The present invention provides methods for restoring and increasing dendritic cell populations in a subject by modulation of the lymphotoxin-β receptor (LTβR) via LTβR agonists. The invention also provides methods for screening for agents capable of restoring or increasing dendritic cell populations. The invention further provides a method for the treatment of immunodeficiency by administration of an LTβR agonist.

摘要翻译： 本发明提供了通过调节淋巴毒素 - 重组来恢复和增加受试者的树突状细胞群的方法。 受体（LT＆bgr; R）通过LT＆bgr R激动剂。 本发明还提供了筛选能够恢复或增加树突细胞群体的试剂的方法。 本发明还提供了通过施用LT＆Bgr R激动剂治疗免疫缺陷的方法。